Image Source: AsiaOne
PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials GlobeNewswire September 18, 2020 RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials. The relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to Microsoft Azure.
Source: AsiaOne